SDC1 and hepatocellular carcinoma: In a small single arm phase 1b study in 15 HCC patients testing neoadjuvant cabozantinib, a tyrosine kinases inhibitor, and nivolumab, TLS were found in R, with an enrichment in T effector cells, TLS, and CD138+ PC.